Press release


Half-yearly report on the liquidity contract
with TP ICAP (Europe) SA

Under the liquidity contract entered into by ABIONYX Pharma with TP ICAP (Europe) SA, the following
assets were included in the liquidity account at June 30, 2025:

• Number of shares: 162,298
• Cash balance: 86,279.52 €


During the 1st half of 2025, a total of :
PURCHASE 223,631 shares 275,707.78 € 253 transactions
SALE 214,077 shares 272,643.70 € 226 transactions

As a reminder, at the half-yearly balance sheet date of December 31, 2024, the following assets were
included in the liquidity account:

• Number of shares: 152,744 shares
• Cash balance: 90,498.64 €


When the liquidity contract was set up, the following resources were made available:

• Number of shares: 131,000 shares
• Cash balance: 40,801.20 €




ANNEX H1 2025
1/5
Purchases Sales
Number
number of Number of Capital in number of
ABNX FP of Capital in EUR
transactions shares EUR transactions
shares
Total 253 223,631 275,707.78 226 214,077 272 ,643.696
20250101 0 0 0,00 0 0 0,00
20250102 1 1 1,20 1 1 1,20
20250103 4 4 731 5 598,24 1 1 1,20
20250106 2 2 151 2 555,39 1 1 1,19
20250107 2 2 091 2 475,76 2 2 2,41
20250108 1 1 1,21 6 16 781 20 838,45
20250109 1 1 1,28 3 4 091 5 261,22
20250110 5 6 674 8 375,50 1 1 1,30
20250113 2 2 321 2 915,20 1 1 1,28
20250114 2 2 251 2 827,26 1 1 1,26
20250115 3 2 283 2 834,77 2 1 364 1 732,25
20250116 2 2 181 2 708,83 2 54 68,58
20250117 1 1 1,27 5 12 861 16 681,79
20250120 2 2 411 3 134,32 3 4 051 5 396,12
20250121 4 5 141 6 583,61 1 1 1,29
20250122 2 2 391 3 003,11 1 1 1,27
20250123 2 2 321 2 910,53 2 98 125,61
20250124 2 2 251 2 827,28 2 3 3,85
20250127 3 3 001 3 731,25 1 1 1,25
20250128 1 1 1,24 1 1 1,24
20250129 4 3 726 4 523,13 1 1 1,24
20250130 2 300 362,40 1 1 1,21
20250131 2 16 19,30 4 8 891 11 103,15
20250203 3 3 141 3 830,03 2 72 90,00
20250204 2 2 251 2 710,21 1 1 1,21
20250205 1 1 1,22 2 2 2,44
20250206 2 2 181 2 630,31 1 1 1,23
20250207 2 2 131 2 544,42 1 1 1,20
20250210 1 1 1,22 2 2 2,44
20250211 1 1 1,20 1 1 1,20
20250212 1 1 1,20 4 6 289 7 736,41
20250213 3 3 011 3 659,43 2 2 2,49
20250214 1 1 1,23 2 2 2,46
20250217 2 250 300,50 3 4 441 5 480,40
20250218 1 1 1,24 4 4 329 5 463,59
20250219 3 3 201 3 941,54 2 392 494,68
20250220 1 1 1,33 6 15 961 21 228,13
20250221 1 1 1,31 2 738 972,68
2/5
20250224 3 3 621 4 697,72 1 1 1,32
20250225 1 1 1,33 5 11 351 15 354,69
20250226 3 3 811 5 134,77 3 3 591 4 962,95
20250227 3 3 821 5 140,51 1 1 1,35
20250228 4 5 691 7 466,21 1 1 1,35
20250303 1 1 1,30 6 12 891 17 168,66
20250304 4 6 181 8 071,89 2 2 2,69
20250305 2 2 2,54 2 1 559 2 023,55
20250306 2 2 921 3 727,21 1 1 1,29
20250307 3 3 871 4 913,61 1 1 1,27
20250310 3 3 721 4 715,77 1 1 1,27
20250311 4 5 571 6 855,74 1 1 1,26
20250312 1 1 1,24 1 1 1,24
20250313 2 424 517,30 3 4 051 5 072,04
20250314 3 3 571 4 439,97 1 1 1,25
20250317 2 2 561 3 129,56 1 1 1,24
20250318 1 1 1,24 1 1 1,24
20250319 2 2 481 3 031,78 1 1 1,22
20250320 2 2 411 2 941,43 3 4 231 5 297,39
20250321 1 1 1,26 7 19 891 25 919,78
20250324 3 3 627 4 672,00 2 972 1 281,10
20250325 2 2 901 3 690,09 1 1 1,29
20250326 1 1 1,29 1 1 1,29
20250327 1 1 1,28 1 1 1,28
20250328 1 1 1,28 1 1 1,28
20250331 2 1 862 2 346,13 1 1 1,27
20250401 5 9 031 11 067,11 1 1 1,27
20250402 4 5 341 6 540,66 1 1 1,24
20250403 3 3 301 4 051,43 1 1 1,23
20250404 5 7 581 9 022,58 1 1 1,24
20250407 7 10 871 12 406,55 1 1 1,19
20250408 2 1 338 1 493,23 5 9 741 11 244,94
20250409 4 4 202 4 770,74 1 1 1,14
20250410 1 1 1,18 5 13 821 16 335,50
20250411 2 2 451 2 857,87 1 1 1,17
20250414 2 911 1 060,43 2 2 2,38
20250415 2 2 351 2 741,29 1 1 1,19
20250416 2 640 744,96 1 1 1,16
20250417 1 1 1,19 2 2 231 2 659,35
20250418 0 0 0,00 0 0 0,00
20250421 0 0 0,00 0 0 0,00
20250422 1 1 1,20 3 4 481 5 386,40
20250423 1 1 1,19 3 4 321 5 280,47
20250424 1 1 1,23 2 413 508,82

3/5
20250425 1 1 1,21 1 1 1,21
20250428 1 1 1,23 2 249 306,27
20250429 2 2 2,44 1 1 1,23
20250430 2 1 865 2 256,68 1 1 1,24
20250501 0 0 0,00 0 0 0,00
20250502 1 1 1,22 2 2 071 2 551,46
20250505 6 10 811 12 763,44 1 1 1,24
20250506 3 3 021 3 629,31 2 2 2,46
20250507 1 1 1,23 1 1 1,23
20250508 1 1 1,21 1 1 1,21
20250509 1 1 1,23 1 1 1,23
20250512 3 2 191 2 629,20 1 1 1,20
20250513 1 1 1,23 2 4 4,93
20250514 1 1 1,23 1 1 1,23
20250515 1 1 1,23 1 1 1,23
20250516 2 2 061 2 493,83 1 1 1,23
20250519 1 1 1,23 1 1 1,23
20250520 1 1 1,21 4 9 071 11 364,29
20250521 1 1 1,24 2 2 2,49
20250522 1 1 1,24 3 4 371 5 455,20
20250523 1 1 1,26 4 8 381 10 768,00
20250526 1 1 1,30 2 2 001 2 601,30
20250527 1 1 1,31 4 7 871 10 396,13
20250528 1 1 1,33 3 3 579 4 767,23
20250529 4 6 071 7 774,61 1 1 1,29
20250530 1 1 1,29 1 1 1,29
20250602 1 1 1,30 2 474 619,98
20250603 1 1 1,31 1 1 1,31
20250604 3 3 771 4 839,51 1 1 1,29
20250605 1 1 1,26 1 1 1,26
20250606 1 1 1,28 1 1 1,28
20250609 1 1 1,28 1 1 1,28
20250610 1 1 1,29 2 1 951 2 520,69
20250611 3 3 002 3 833,87 1 1 1,30
20250612 3 3 621 4 589,10 1 1 1,30
20250613 3 3 511 4 400,52 1 1 1,26
20250616 2 300 372,00 1 1 1,24
20250617 1 1 1,25 1 1 1,25
20250618 2 961 1 180,13 1 1 1,25
20250619 1 1 1,25 1 1 1,25
20250620 2 2 491 3 058,95 1 1 1,23
20250623 3 3 301 4 031,62 1 1 1,22
20250624 1 1 1,23 1 1 1,23
20250625 2 2 361 2 852,09 1 1 1,21

4/5
20250626 1 1 1,23 1 1 1,23
20250627 1 1 1,23 1 1 1,23
20250630 4 4 761 5 678,38 1 1 1,20


About ABIONYX Pharma
ABIONYX Pharma is a new-generation biotechnology company whose aim is to contribute to healthcare through innovative
therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in
research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to offer drugs for the
treatment of kidney and ophthalmological diseases, or new apoA-1 vectors used for targeted drug delivery.


Contacts
NewCap NewCap
Investor Relations Media Relations
Louis-Victor Delouvrier Arthur Rouillé
abionyx@newcap.eu abionyx@newcap.eu
+33 (0)1 44 71 98 53 +33 (0)1 44 71 00 15




5/5